Drug intelligence / Profile preview

NT020

Development stage: Preclinical
Lead developer: Chengdu New Radiomedicine Technology
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

NT020 is an investigational radioligand therapy (RLT) being developed by Chengdu New Radiomedicine Technology (NRT) for the treatment of solid tumors. Currently in the preclinical and IND-enabling stages, the drug is designed to selectively target tumor cells and deliver a therapeutic radioactive payload to induce localized cytotoxicity. While the specific molecular target and the radioisotope (such as Lutetium-177 or Actinium-225) have not been publicly disclosed, the program is a key component of NRT's pipeline focused on innovative radiopharmaceuticals for oncology.

Beyond the preview

Go deeper on NT020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NT020.

Explore the full profile